IntronX is a biotechnology company developing small molecule therapeutics based on the deep expertise in RNA structure and RNA splicing within the Pyle laboratory at Yale University.  The company has a proprietary screening platform for monitoring the selective inhibition of individual RNA splicing events that has enabled the discovery of novel, validated RNA targets within pathogenic fungal organisms.   IntronX discovery platform generated potent small molecule inhibitors of fungal RNA metabolism that lack toxicity in human cells. These compounds represent a new class of selective drugs for treating the growing threat of systemic fungal infections.  IntronX is a diversified company with existing small molecule assets, a proprietary screening platform and a discovery engine for new compounds against microbial targets and dysregulated human splicing events. IntronX has a nimble and staged development plan to advance its discovery platform and pre-clinical compounds.